Literature DB >> 16821090

PTEN inhibits adrenomedullin expression and function in brain tumor cells.

Simone A Betchen1, Sergei Musatov, Jill Roberts, John Pena, Michael G Kaplitt.   

Abstract

Adrenomedullin is a vasoactive peptide that is upregulated in higher-grade gliomas and promotes tumor cell proliferation. Since reduced activity of the anti-oncogene PTEN seems to also correlate with higher tumor grade, this suggests an inverse association between PTEN activity and adrenomedullin expression. PC12 pheochromocytoma and human U251 glioma cell lines were stably transfected with human PTEN or control plasmid. Adrenomedullin expression was analyzed using quantitative PCR and Western blotting. A cell proliferation assay was used to assess adrenomedullin effects on U251 cells overexpressing PTEN. PC12 and U251 cells overexpressing PTEN had 17- and 8-fold decreases in adrenomedullin mRNA levels, respectively, compared to control cells. Cellular and secreted adrenomedullin peptide was similarly reduced. Addition of adrenomedullin to medium of controlled cells induced proliferation, as described previously, but U251 cells overexpressing PTEN did not respond to exogenous adrenomedullin. Further exploration revealed that PTEN also inhibits expression of the gliomas receptor for adrenomedullin, which accounts for this effect. These data were all replicated with an inducible PTEN construct confirming that these effects are not exclusively secondary to chronic overexpression. Given the profound effects of adrenomedullin on tumor cells, this is a novel and previously unidentified mechanism by which alterations in PTEN levels or function may influence tumor growth.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16821090     DOI: 10.1007/s11060-005-9035-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin.

Authors:  K Ehlenz; B Koch; P Preuss; B Simon; I Koop; R E Lang
Journal:  Exp Clin Endocrinol Diabetes       Date:  1997       Impact factor: 2.949

2.  Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN.

Authors:  M Matsushima-Nishiu; M Unoki; K Ono; T Tsunoda; T Minaguchi; H Kuramoto; M Nishida; T Satoh; T Tanaka; Y Nakamura
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 3.  Adrenomedullin receptors: molecular identity and function.

Authors:  D L Hay; D M Smith
Journal:  Peptides       Date:  2001-11       Impact factor: 3.750

4.  PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.

Authors:  Myung-Jin Park; Mi-Suk Kim; In-Chul Park; Hee-Seok Kang; Heon Yoo; Seok Hee Park; Chang Hun Rhee; Seok-Il Hong; Seung-Hoon Lee
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

5.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

6.  Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector.

Authors:  C A Strathdee; M R McLeod; J R Hall
Journal:  Gene       Date:  1999-03-18       Impact factor: 3.688

Review 7.  Protean PTEN: form and function.

Authors:  Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

8.  Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis.

Authors:  Martin K Oehler; Stephen Hague; Margaret C P Rees; Roy Bicknell
Journal:  Oncogene       Date:  2002-04-25       Impact factor: 9.867

9.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

10.  PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.

Authors:  Liang-Ping Weng; Jessica L Brown; Kim M Baker; Michael C Ostrowski; Charis Eng
Journal:  Hum Mol Genet       Date:  2002-07-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.